Explore

Trendline Trendline
Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA Combination

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA Combination

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA Combination
Trendline Trendline
Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Oncology Pipeline

Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Oncology Pipeline

Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Oncology Pipeline
Trendline Trendline
Kali Therapeutics to Present KT209 Trispecific Antibody at EHA 2026 Congress

Kali Therapeutics to Present KT209 Trispecific Antibody at EHA 2026 Congress

Kali Therapeutics to Present KT209 Trispecific Antibody at EHA 2026 Congress
Trendline Trendline
Shuttle Pharma Announces 10-for-1 Reverse Stock Split to Strengthen Capital Structure

Shuttle Pharma Announces 10-for-1 Reverse Stock Split to Strengthen Capital Structure

Shuttle Pharma Announces 10-for-1 Reverse Stock Split to Strengthen Capital Structure
Trendline Trendline
Savara Announces Leadership Transition as CFO Steps Down for Health Reasons

Savara Announces Leadership Transition as CFO Steps Down for Health Reasons

Savara Announces Leadership Transition as CFO Steps Down for Health Reasons
Trendline Trendline
IGC Pharma's Alzheimer's Drug Trial Progress Boosts Stock Target

IGC Pharma's Alzheimer's Drug Trial Progress Boosts Stock Target

IGC Pharma's Alzheimer's Drug Trial Progress Boosts Stock Target
Trendline Trendline
Johnson Johnson Acquires Firefly Bio to Enhance Oncology Pipeline with Innovative Platform

Johnson Johnson Acquires Firefly Bio to Enhance Oncology Pipeline with Innovative Platform

Johnson Johnson Acquires Firefly Bio to Enhance Oncology Pipeline with Innovative Platform
Trendline Trendline
Eloxx Pharmaceuticals Announces $66 Million Public Offering and Nasdaq Uplisting

Eloxx Pharmaceuticals Announces $66 Million Public Offering and Nasdaq Uplisting

Eloxx Pharmaceuticals Announces $66 Million Public Offering and Nasdaq Uplisting
Trendline Trendline
Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Cancer Treatment

Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Cancer Treatment

Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Cancer Treatment
Trendline Trendline
AbCellera Appoints Dr. Victor Sandor to Board of Directors, Enhancing Leadership in Antibody Discovery

AbCellera Appoints Dr. Victor Sandor to Board of Directors, Enhancing Leadership in Antibody Discovery

AbCellera Appoints Dr. Victor Sandor to Board of Directors, Enhancing Leadership in Antibody Discovery
Trendline Trendline
SpaceX IPO Set to Trigger Major Stock Market Volatility as Investors Reallocate Funds

SpaceX IPO Set to Trigger Major Stock Market Volatility as Investors Reallocate Funds

SpaceX IPO Set to Trigger Major Stock Market Volatility as Investors Reallocate Funds
Trendline Trendline
Business Insider and Plant-A Insights Recognize America's High-Growth Companies for 2026

Business Insider and Plant-A Insights Recognize America's High-Growth Companies for 2026

Business Insider and Plant-A Insights Recognize America's High-Growth Companies for 2026